Portfolio

We are enabling companies to turn their boldest ambitions into world-changing breakthroughs in healthcare and technology.

Portfolio

Spotlights Portfolio List

Portfolio List

Develops innovative embolotherapy using inorganic polymer microspheres for hypervascular tumors.
Develops protein conjugate therapies, combining biologics and small molecule payloads to treat cancer.
Uses genome-wide methylation analysis for earlier, precise cancer and morbidity detection.
Developing a protein nanoparticle (PNP) delivery platform.
Develops transformative gene therapies for devastating diseases using rationally designed AAV vectors.
Develops targeted radioligand therapies (RLTs) to improve cancer treatment globally.
Develops precision medicines targeting protein synthesis for breakthrough cancer therapies.
Developing Amber-UI neuromodulation therapy using Picostim for urinary incontinence.
Develops alpha radioligand therapies (ARTs) for targeted cancer treatment with resilient supply chain.
Developing neurodegenerative disease treatments using proprietary RNA interference platform.
Develops improved therapies for idiopathic pulmonary fibrosis (IPF) and other respiratory diseases.
Develops CAR-T cell therapies using switchable and scalable platforms for cancers.
Pioneering gene therapy company focused on transformative medicines for neurodegenerative disorders.
Developing innovative neuromodulation technology to treat large disease populations.
Specializes in distributed ledger infrastructure for major financial institutions, workflow automation.
Develops innovative orthopedic solutions to restore patient mobility and enhance surgical outcomes.
Develops and commercializes novel digital programmable hearing aid solutions for China.
Developed a CE-Marked product for improving dialysis access surgery.
Developing base editing technology for a range of applications.
Develops and commercializes high-quality hyaluronic acid (HA) based products for the Chinese market.
Develops therapies for epilepsy and other neurological disorders with neural implant technology.
Provides affordable, convenient, and effective orthodontic solutions through clear aligners and remote monitoring.
Rapidly growing pharmaceutical company focusing on emerging markets and expanding into regulated markets.
Employs DragonFold technology for rapid protein/ligand co-folding to develop novel drugs.
Develops and commercializes consumer healthcare and over-the-counter products.
Developing the first therapy targeting a root cause of preterm preeclampsia to reduce risks for mothers and babies, including premature birth.
Redefining PCR with single-molecule precision and category-defining sensitivity.
Leader in discovery and development of novel drugs in stem cell related diseases.
Seed-stage venture firm and accelerator for therapeutics startups, providing expertise and capital.
Developing curative medicines through precision in vivo cellular engineering.
Specializing in biosimilars and novel biologics for global healthcare markets.
Focused on affordable, high-quality medicines for patients worldwide.
Improving diagnostic testing and accelerate drug discovery in diverse underserved populations.
Hemostatic product manufacturer in China.
Leading the change in cell & gene therapies & personalized immunotherapy.
Dedicated to developing novel treatments for fibrotic diseases.
Harnessing deep learning to accelerate pharmaceutical development.
Developing novel treatments for unmet medical needs.
Targets epigenetic pathways to develop innovative cancer therapies.
Develops and produces insulin pumps.
Developing nasal spray products to prevent respiratory viruses.
Manufactures, develops, and commercializes high quality, affordably priced cardiovascular and general surgery medical devices.
Bringing cell-based therapies to heart failure patients.
Manufactures and markets minimally invasive interventional therapy medical devices in the field of ENT, cardiovascular and others.
Develops targeted therapies for fibrotic diseases and other dermatological conditions.
Developing novel therapeutics for neurogenic cough and inflammation.
Developing small molecule inhibitors of the NLRP3 inflammasome.
Provides cryptocurrency compliance for virtual asset service providers and financial institutions.
Accelerating the advancement of globally competitive oncology assets for patients.
Promotes the development of cervical cancer screening and prevention in China.
Offers clean-label wellness supplements for health-conscious consumers through plant-based nutrition.
Developing and introducing effective and clinically proven children's medicines for China.
Designing novel therapeutics against previously undruggable targets using experimental and computational biophysics.
Developing and supplying plasma protein therapies for the treatment of rare and chronic diseases.
Developing therapies for neuropsychiatric and neurodevelopmental disorders.
Developing inhaled therapies for severe respiratory infections and lung conditions.
Developing precision diagnostic solutions for cell analysis and research.
Developing and commercializing therapies for rare diseases in Asia.
Providing quality medical equipment and supporting healthcare professionals and patients.
Developing gene therapies for retinal diseases causing blindness.
Developing RNA-based therapeutics for immune modulation and viral defense.
Developing therapies that target aging at the cellular level.
Pioneering novel immunotherapies for cancer treatment.
Facilitating data-driven life science research and empowering drug R&D processes.
Developing treatments for age-related degenerative diseases.
Developing innovative treatments for genetic diseases through gene therapy.
Advancing TCR bispecific therapies for cancer and autoimmune disorders.
Transforming global drug discovery with advanced AI and physics-based technologies.
Developing a novel therapy to treat presbyopia.
Improving the lives of patients and caregivers impacted by neurological, cardiometabolic, and ophthalmic diseases.
Developing diagnostic and imaging solutions for healthcare providers.
Developing minimally invasive treatments for benign prostatic hyperplasia.
The companies identified do not represent all the companies purchased, sold, or recommended for portfolios advised by F-Prime.